Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by CytochromePon Apr 02, 2017 10:05am
148 Views
Post# 26064516

RE:RE:RE:RE:Am I the only one...

RE:RE:RE:RE:Am I the only one...Nope, plants aren't like machines. Clones grown next to eachother can have wildly different concentrations of certain metabolites. The plant I work on has ~30% variance in alkaloid between clones grown in vitro. Alkaloids, like THCs and CBDs, are specialized metabolites so their biosynthesis and deposition aren't as tightly regulated as auxin, for example. It amazes me that they can produce strains with THCs/CBDs levels within a smallish threshold. Aphria has shown that greenhouse vs indoors plays no role in this small variance, are you assume here. If you want to know why Aphria doesn't go full indoors look at your hydro bill.

doobiebaby wrote: Aces, thanks for that post. Never heard it stated that well before. I have wondered why Aphria is so reluctant to get into indoor grow since Bedrocan insists on it for consistency each and every time. I knew you had to control all the inputs to get the same output of harvest time after time. But I did not know about this certification difference which is critically important I would think from a medical perspective. Rec I don't think matters as much...although I think people want excellent consistency in the strains they are interested in...but for medical it has to be the same dose every time to be Pharma grade. Thanks for bringing up the certification issue.


Bullboard Posts